Corvus Pharmaceuticals, Inc.
CRVS
$15.97
$0.161.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.02% | 13.34% | 18.83% | 24.86% | 19.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.53% | 55.99% | 54.99% | 52.04% | 35.35% |
| Operating Income | -53.53% | -55.99% | -54.99% | -52.04% | -35.35% |
| Income Before Tax | -6.69% | 75.47% | 73.47% | -99.57% | -66.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.69% | 75.47% | 73.47% | -99.57% | -66.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.69% | 75.47% | 73.47% | -99.57% | -66.55% |
| EBIT | -53.53% | -55.99% | -54.99% | -52.04% | -35.35% |
| EBITDA | -53.58% | -56.09% | -55.17% | -52.31% | -35.67% |
| EPS Basic | 17.93% | 83.13% | 79.27% | -50.77% | -25.32% |
| Normalized Basic EPS | 17.90% | 83.14% | 79.27% | -50.77% | -25.27% |
| EPS Diluted | 46.53% | 47.91% | 42.49% | -125.78% | -90.97% |
| Normalized Diluted EPS | 18.97% | 82.26% | 78.36% | -52.67% | -26.93% |
| Average Basic Shares Outstanding | 24.99% | 29.49% | 34.12% | 37.82% | 37.18% |
| Average Diluted Shares Outstanding | 23.58% | 30.73% | 35.47% | 39.28% | 38.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |